Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Thursday

Bicara Therapeutics (NASDAQ:BCAX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Bicara Therapeutics to post earnings of ($0.72) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 30, 2026 at 8:30 AM ET.

Bicara Therapeutics Stock Performance

BCAX stock opened at $18.16 on Wednesday. Bicara Therapeutics has a 1 year low of $7.80 and a 1 year high of $20.25. The stock has a market capitalization of $994.80 million, a price-to-earnings ratio of -8.11 and a beta of -0.78. The stock’s fifty day moving average is $17.01 and its two-hundred day moving average is $16.42.

Insider Buying and Selling at Bicara Therapeutics

In related news, CEO Claire Mazumdar sold 1,596 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $18.95, for a total value of $30,244.20. Following the completion of the transaction, the chief executive officer owned 339,392 shares in the company, valued at $6,431,478.40. This trade represents a 0.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Raben sold 16,300 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total value of $301,876.00. Following the sale, the insider owned 55,286 shares in the company, valued at approximately $1,023,896.72. The trade was a 22.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 128,769 shares of company stock valued at $2,415,814 in the last ninety days.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in Bicara Therapeutics by 701.4% in the 4th quarter. California State Teachers Retirement System now owns 17,158 shares of the company’s stock worth $289,000 after purchasing an additional 15,017 shares during the period. Algert Global LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $278,000. Jane Street Group LLC acquired a new stake in Bicara Therapeutics during the 2nd quarter valued at $266,000. VARCOV Co. purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at $263,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Bicara Therapeutics in the second quarter valued at $255,000.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Citizens Jmp started coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 target price for the company. Citigroup assumed coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating on the stock. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.25.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.